Pendahuluan: Anosmia merupakan salah satu karakteristik klinis pasien COVID-19. Anosmia dilaporkan sebagai gejala pertama sebelum gejala yang lain. Penelitian sebelumnya menunjukkan anosmia berimplikasi sebagai faktor prognosis protektif pada pasien COVID-19. Melalui penelitian ini diharapkan dapat menggambarkan karakteristik pasien COVID-19 dengan gejala anosmia serta hubungannya dengan derajat keparahan.Metode: Penelitian studi deskriptif, cross-sectional, retrospektif dengan jumlah sampel 149 pasien dikonfirmasi COVID-19. Penelitian ini dilakukan pada pasien rawat inap mulai tanggal 01 Maret hingga 31 Juli 2020 di rumah sakit Primasatya Husada Citra Surabaya (RS PHC Surabaya). Pasien COVID-19 dibagi menjadi dua grup yaitu dengan dan tanpa gejala anosmia. Karakteristik klinis pasien dideskripsikan pada tabel dan dilakukan penghitungan odd ratio untuk mengetahui faktor risiko terjadinya derajat keparahan berat pada pasien COVID-19.Hasil: Pasien yang mengalami anosmia rata-rata berusia 32 tahun dengan jenis kelamin perempuan lebih banyak (63,2%), pasien dengan gejala anosmia didapatkan lebih banyak pasien dengan derajat keparahan rendah (89,5%) dengan odd ratio terjadinya derajat keparahan berat 0,479. Pasien dengan gejala anosmia disertai dengan gejala lain seperti batuk, rinorea, nyeri tenggorokan, sesak, nyeri kepala, dan nyeri otot (p < 0,05).Kesimpulan: Pasien COVID-19 dengan gejala anosmia memiliki derajat keparahan yang lebih ringan dibandingkan pasien yang tanpa gejala anosmia.
Introduction:The prevalence of Rhinitis Allergy (RA) is quite high, reaching 32%. The incidence of RA is often associated with asthma, as many as 45% of asthmatics occur after RA, and as many as 20-50% of RA occur after asthma. If RA occurs together with asthma, it can exacerbate clinical symptoms for the patient. According to ARIA-WHO, RA is classified according to time, into intermittent and persistent, and based on the severity of symptoms and quality of life, divided into mild and moderate-severe. Currently, there is a short questionnaire, namely the Total Nasal Symptom Score (TNSS). TNSS is the sum of individual scores for each nasal symptom. Each symptom was measured using a score of 0 to 3. Purpose: To determine the correlation between TNSS and RA classification based on ARIA-WHO with asthma comorbidity at PHC Hospital in Surabaya. Method: This study used an observational analytic research design with a cross-sectional study design, with a sample size of 39. Statistical analysis was carried out using the Spearman Correlation test. Result: From 39 samples, female (59%) and male (41%), the highest age group was 46-55 years (28.2%), the most allergy history was allergy to cold and dust (67.9%), the highest degree of TNSS was mild (43.6%) followed by moderate (33.3%), then severe (12.8%) and very mild (10.3%). The highest degree of RA was persistent moderate-severe (51.3%), followed by mild persistent (17.9%), followed by intermittent mild and intermittent moderate-severe (15.4%). Based on the analysis results that have been carried out using the Spearman correlation test, the results are p = 0.000 (α = <0.05) and r = 0.566, showing a strong significant correlation. Conclusion: There is a strong significant correlation between TNSS and RA classification based on ARIA-WHO in RA patients with asthma comorbidity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.